Total Payments
$282,543
2024 Payments
$55,244
Companies
21
Transactions
410
Medicare Patients
12,193
Medicare Billing
$15.6M
Payment Breakdown by Category
Other$171,451 (60.7%)
Consulting$63,209 (22.4%)
Travel$32,089 (11.4%)
Food & Beverage$8,768 (3.1%)
Research$7,025 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $171,419 | 37 | 60.7% |
| Consulting Fee | $63,209 | 26 | 22.4% |
| Travel and Lodging | $32,089 | 117 | 11.4% |
| Food and Beverage | $8,768 | 225 | 3.1% |
| Unspecified | $7,025 | 4 | 2.5% |
| Entertainment | $31.63 | 1 | 0.0% |
Payments by Type
General
$275,518
406 transactions
Research
$7,025
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $167,616 | 210 | $0 (2024) |
| Genentech USA, Inc. | $77,235 | 127 | $0 (2024) |
| F. Hoffmann-La Roche AG | $12,978 | 6 | $0 (2021) |
| Astellas Pharma US Inc | $9,658 | 18 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,632 | 4 | $0 (2024) |
| Vital Art and Science, LLC | $4,486 | 1 | $0 (2017) |
| EyePoint Pharmaceuticals US, Inc. | $1,754 | 6 | $0 (2024) |
| Allergan, Inc. | $227.02 | 7 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $220.31 | 4 | $0 (2019) |
| Alimera Sciences, Inc. | $169.95 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,244 | 62 | Regeneron Healthcare Solutions, Inc. ($36,324) |
| 2023 | $731.70 | 24 | Regeneron Healthcare Solutions, Inc. ($242.28) |
| 2022 | $1,371 | 14 | Regeneron Healthcare Solutions, Inc. ($1,239) |
| 2021 | $7,805 | 12 | F. Hoffmann-La Roche AG ($5,953) |
| 2020 | $49,063 | 58 | Regeneron Healthcare Solutions, Inc. ($41,944) |
| 2019 | $48,676 | 81 | Regeneron Healthcare Solutions, Inc. ($44,300) |
| 2018 | $41,056 | 60 | Regeneron Healthcare Solutions, Inc. ($21,267) |
| 2017 | $78,595 | 99 | Genentech USA, Inc. ($53,466) |
All Payment Transactions
410 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,582.33 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,350.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,000.00 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Travel and Lodging | Cash or cash equivalent | $782.90 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Travel and Lodging | Cash or cash equivalent | $197.32 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $121.33 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Ophthalmology | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $500.65 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $278.72 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 10/30/2024 | Harrow Eye, LLC | IHEEZO (Drug), TRIESENCE | Food and Beverage | In-kind items and services | $77.79 | General |
| Category: OPTOMETRY | ||||||
| 10/24/2024 | Astellas Pharma US Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| 10/09/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Ophthalmology | ||||||
| 09/26/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/17/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $111.83 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/26/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $92.72 | General |
| Category: Ophthalmology | ||||||
| 08/14/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $32.12 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: Ophthalmology | ||||||
| 08/08/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Baseline diabetic retinopathy severity affects time to clinically meaningful improvements in diabetic retinopathy during ranibizumab treatment | F. Hoffmann-La Roche AG | $4,161 | 2 |
| Baseline Diabetic Retinopathy Severity Affects Time to Clinically Meaningful Improvements in Diabetic Retinopathy During Ranibizumab Treatment | F. Hoffmann-La Roche AG | $1,997 | 1 |
| Baseline Diabetic Retinopathy Severity Affects Time to Clinically Meaningful Improvements in Diabetic Retinopathy During Ranibizumab Treatment. | F. Hoffmann-La Roche AG | $867.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 3,106 | 18,800 | $10.0M | $3.8M |
| 2022 | 16 | 3,176 | 14,811 | $9.5M | $4.1M |
| 2021 | 18 | 3,548 | 14,357 | $10.0M | $4.5M |
| 2020 | 11 | 2,363 | 10,271 | $7.0M | $3.3M |
Total Patients
12,193
Total Services
58,239
Medicare Billing
$15.6M
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 334 | 2,714 | $3.4M | $1.9M | 55.5% |
| J3490 | Unclassified drugs | Office | 2023 | 213 | 428 | $2.9M | $957,819 | 33.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 34 | 8,700 | $435,000 | $252,168 | 58.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 472 | 1,893 | $1.5M | $172,458 | 11.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 42 | 870 | $487,200 | $163,095 | 33.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 601 | 923 | $170,755 | $78,686 | 46.1% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 33 | 332 | $398,400 | $71,909 | 18.0% |
| 92134 | Imaging of retina | Office | 2023 | 847 | 2,124 | $297,360 | $59,282 | 19.9% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 16 | 250 | $140,000 | $43,520 | 31.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 200 | 200 | $50,100 | $22,815 | 45.5% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 18 | 20 | $88,000 | $17,478 | 19.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 204 | 250 | $35,543 | $14,503 | 40.8% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 13 | 14 | $61,600 | $12,659 | 20.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 20 | 20 | $4,000 | $2,045 | 51.1% |
| 92250 | Photography of the retina | Office | 2023 | 59 | 62 | $7,440 | $1,613 | 21.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 415 | 4,258 | $5.3M | $3.1M | 57.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 113 | 2,424 | $1.4M | $546,497 | 40.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 503 | 2,301 | $1.8M | $212,289 | 11.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 663 | 1,090 | $201,650 | $93,581 | 46.4% |
| 92134 | Imaging of retina | Office | 2022 | 908 | 2,391 | $334,740 | $68,300 | 20.4% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 14 | 1,680 | $143,400 | $50,133 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 218 | 218 | $54,500 | $24,790 | 45.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 196 | 238 | $33,796 | $14,704 | 43.5% |
| 67041 | Removal of membrane of retina | Facility | 2022 | 16 | 16 | $70,400 | $13,995 | 19.9% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2022 | 15 | 17 | $56,848 | $11,681 | 20.5% |
About Dr. Mitchell Goff, M.D
Dr. Mitchell Goff, M.D is a Retina Specialist healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578595153.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitchell Goff, M.D has received a total of $282,543 in payments from pharmaceutical and medical device companies, with $55,244 received in 2024. These payments were reported across 410 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($171,419).
As a Medicare-enrolled provider, Goff has provided services to 12,193 Medicare beneficiaries, totaling 58,239 services with total Medicare billing of $15.6M. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Location Salt Lake City, UT
- Active Since 07/06/2006
- Last Updated 11/26/2024
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1578595153
Products in Payments
- EYLEA (Biological) $89,505
- Lucentis (Biological) $77,937
- EYLEA HD (Biological) $43,986
- EYLEA AFLIBERCEPT INJECTION (Biological) $41,757
- Izervay (Drug) $8,502
- Non-Covered Product (Drug) $6,371
- mVT(R) Service (Device) $4,486
- EYP-1901 (Drug) $1,582
- OZURDEX (Drug) $260.65
- YUTIQ (Drug) $201.45
- ACTHAR (Biological) $88.64
- IHEEZO (Drug) $77.79
- VABYSMO (Drug) $63.90
- ILUVIEN (Drug) $57.34
- Vabysmo (Drug) $35.83
- P200DTx (Device) $31.63
- Syfovre (Drug) $31.11
- Iluvien (Drug) $30.99
- STAR S4 IR Excimer Laser System (Device) $24.34
- EVA Ophthalmic Surgical System (Device) $22.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Retina Specialist Doctors in Salt Lake City
David Faber, M.d, M.D
Retina Specialist — Payments: $32,514
Retina Specialist $32,514
Prof. Marc Steffen Schmitz-Valckenberg, Md, MD
Retina Specialist — Payments: $32,172
Retina Specialist $32,172
Dr. Rebekah Gensure, M.d., Ph.d, M.D., PH.D
Retina Specialist — Payments: $1,468
Retina Specialist $1,468